Legend Biotech (LEGN) Free Cash Flow (2019 - 2026)
Legend Biotech's (LEGN) quarterly Free Cash Flow came in at -$92.6 million in Q1 2026, up 12.31% YoY from -$82.4 million in Q1 2025, and down 659.02% on a QoQ basis from -$12.2 million in Q4 2025.
Legend Biotech (LEGN) Free Cash Flow (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Free Cash Flow data on file, last reported at -$92.6 million in Q1 2026.
- Quarterly Free Cash Flow rose 12.31% year-over-year to -$92.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$71.0 million (up 75.67% YoY) and the FY2025 annual result came in at -$100.2 million, up 36.62% from the prior year.
- Free Cash Flow declined to -$92.6 million in Q1 2026, from -$12.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $33.8 million in Q3 2025 to a low of -$134.9 million in Q1 2023.
- A 5-year average of -$54.9 million and a median of -$69.5 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow slumped 972.82% — and 2025, when it surged 144.37%.
- Tracing LEGN's Free Cash Flow over 5 years: stood at -$28.8 million in 2022, then tumbled by 356.25% to -$131.5 million in 2023, then rose by 17.9% to -$107.9 million in 2024, then soared by 88.7% to -$12.2 million in 2025, then slumped by 659.02% to -$92.6 million in 2026.
- The last three Free Cash Flow figures came in at -$92.6 million (Q1 2026), -$12.2 million (Q4 2025), and $33.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | -28.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.40 Mn |
| Jun 30, 2026 | -28.40 Mn |
| Mar 31, 2026 | -92.60 Mn |
| Mar 31, 2026 | -92.60 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Sep 30, 2025 | 33.81 Mn |
| Sep 30, 2025 | 33.81 Mn |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | -105.60 Mn |
| Mar 31, 2025 | -105.60 Mn |
| Dec 31, 2024 | -107.93 Mn |
| Dec 31, 2024 | -107.93 Mn |
| Sep 30, 2024 | -76.20 Mn |
| Sep 30, 2024 | -76.20 Mn |
| Jun 30, 2024 | -1.95 Mn |
| Jun 30, 2024 | -1.95 Mn |
| Mar 31, 2024 | 21.76 Mn |
| Mar 31, 2024 | 21.76 Mn |